Gotham Asset Management LLC Grows Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Gotham Asset Management LLC lifted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 11.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,359 shares of the medical research company’s stock after buying an additional 3,303 shares during the quarter. Gotham Asset Management LLC’s holdings in IQVIA were worth $6,162,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Smith Group Asset Management LLC bought a new position in IQVIA in the 4th quarter worth about $1,616,000. Hickory Asset Management Inc. bought a new position in IQVIA in the 4th quarter worth about $941,000. Fifth Third Bancorp boosted its stake in IQVIA by 13.0% in the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock worth $2,590,000 after purchasing an additional 1,521 shares in the last quarter. Graphene Investments SAS boosted its stake in IQVIA by 22.0% in the 4th quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company’s stock worth $2,948,000 after purchasing an additional 2,700 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on IQV shares. Robert W. Baird dropped their price target on shares of IQVIA from $195.00 to $161.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 7th. Morgan Stanley upped their target price on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. Hsbc Global Res cut shares of IQVIA from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 25th. UBS Group lowered their target price on shares of IQVIA from $255.00 to $185.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $270.00 target price on shares of IQVIA in a research note on Monday, February 10th. Eight research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average target price of $231.71.

IQVIA Price Performance

Shares of NYSE:IQV opened at $150.74 on Wednesday. The firm’s 50 day moving average price is $162.61 and its 200-day moving average price is $187.42. IQVIA Holdings Inc. has a twelve month low of $135.97 and a twelve month high of $252.88. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a market capitalization of $26.08 billion, a PE ratio of 20.10, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.07. The company had revenue of $3.83 billion during the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The firm’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.54 EPS. Equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.